Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, remains a significant global health challenge requiring complex and lengthy pharmacotherapy. For PharmD students, a robust understanding of TB management is essential, from differentiating between latent TB infection (LTBI) and active disease to navigating the intricacies of multi-drug regimens. This quiz covers the cornerstone of TB treatment, RIPE therapy, focusing on the mechanisms, adverse effects, and monitoring parameters for first-line agents. It also delves into the treatment of LTBI, the growing problem of drug-resistant TB (MDR-TB), and the pharmacist’s vital role in patient education and promoting adherence through strategies like Directly Observed Therapy (DOT).
1. The standard first-line, four-drug regimen for treating active tuberculosis is known by the acronym RIPE. This includes Rifampin, Isoniazid, Pyrazinamide, and which other drug?
- a) Erythromycin
- b) Ethambutol
- c) Efavirenz
- d) Etanercept
Answer: b) Ethambutol
2. What is the primary mechanism of action of Isoniazid (INH)?
- a) It inhibits bacterial DNA-dependent RNA polymerase.
- b) It disrupts the plasma membrane of the mycobacteria.
- c) It inhibits the synthesis of mycolic acids, a key component of the mycobacterial cell wall.
- d) It inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Answer: c) It inhibits the synthesis of mycolic acids, a key component of the mycobacterial cell wall.
3. A patient starting on isoniazid should be co-prescribed which vitamin to prevent peripheral neuropathy?
- a) Vitamin C
- b) Vitamin D
- c) Folic Acid
- d) Pyridoxine (Vitamin B6)
Answer: d) Pyridoxine (Vitamin B6)
4. A patient taking rifampin should be counseled about a common, harmless side effect that causes a change in the color of their bodily fluids. What color is expected?
- a) Blue-green
- b) Black
- c) Red-orange
- d) Bright yellow
Answer: c) Red-orange
5. Which of the first-line TB drugs requires baseline and monthly monitoring of visual acuity and color discrimination due to its risk for causing optic neuritis?
- a) Rifampin
- b) Isoniazid
- c) Pyrazinamide
- d) Ethambutol
Answer: d) Ethambutol
6. All four first-line RIPE therapy drugs carry a risk for which serious adverse effect, requiring baseline and routine monitoring of liver function tests (LFTs)?
- a) Nephrotoxicity
- b) Cardiotoxicity
- c) Hepatotoxicity
- d) Ototoxicity
Answer: c) Hepatotoxicity
7. Pyrazinamide is an essential part of the initial phase of TB treatment but can cause which metabolic abnormality?
- a) Hypoglycemia
- b) Hyperkalemia
- c) Hyperuricemia, which can precipitate gout flares.
- d) Hyponatremia
Answer: c) Hyperuricemia, which can precipitate gout flares.
8. What is the standard duration of the initial (intensive) phase of treatment for drug-susceptible active pulmonary TB?
- a) 2 weeks
- b) 1 month
- c) 2 months
- d) 4 months
Answer: c) 2 months
9. After the initial phase, the continuation phase for drug-susceptible active pulmonary TB typically consists of which two drugs for a duration of four months?
- a) Pyrazinamide and Ethambutol
- b) Isoniazid and Rifampin
- c) Rifampin and Ethambutol
- d) Isoniazid and Pyrazinamide
Answer: b) Isoniazid and Rifampin
10. A positive tuberculin skin test (TST) in a healthy person with no known risk factors is generally defined as an induration of what size?
- a) ≥ 5 mm
- b) ≥ 10 mm
- c) ≥ 15 mm
- d) Any visible reaction
Answer: c) ≥ 15 mm
11. Which of the following is an advantage of an Interferon-Gamma Release Assay (IGRA) over a Tuberculin Skin Test (TST) for diagnosing latent TB infection?
- a) IGRA is less expensive.
- b) IGRA results are not affected by prior BCG vaccination.
- c) IGRA does not require a blood draw.
- d) IGRA results are available immediately.
Answer: b) IGRA results are not affected by prior BCG vaccination.
12. Which of the following is a preferred short-course regimen for the treatment of Latent TB Infection (LTBI)?
- a) 6 months of pyrazinamide.
- b) 3 months of once-weekly isoniazid plus rifapentine.
- c) 1 month of ethambutol.
- d) 9 months of RIPE therapy.
Answer: b) 3 months of once-weekly isoniazid plus rifapentine.
13. A patient is diagnosed with multidrug-resistant TB (MDR-TB). By definition, the M. tuberculosis isolate is resistant to at least which two drugs?
- a) Pyrazinamide and Ethambutol
- b) Rifampin and Ethambutol
- c) Isoniazid and Rifampin
- d) Isoniazid and Pyrazinamide
Answer: c) Isoniazid and Rifampin
14. Rifampin is a potent inducer of many cytochrome P450 enzymes. This leads to a clinically significant drug interaction with which of the following medications?
- a) Warfarin
- b) Oral contraceptives
- c) Many protease inhibitors used for HIV
- d) All of the above
Answer: d) All of the above
15. What is Directly Observed Therapy (DOT)?
- a) A diagnostic imaging technique for TB.
- b) A strategy where a healthcare worker watches the patient swallow every dose of medication.
- c) A type of surgical intervention for TB.
- d) Self-administration of TB medications at home.
Answer: b) A strategy where a healthcare worker watches the patient swallow every dose of medication.
16. Which of the following is a symptom of active pulmonary TB?
- a) Productive cough lasting more than 3 weeks.
- b) Unexplained weight loss.
- c) Night sweats.
- d) All of the above.
Answer: d) All of the above
17. The mechanism of action of rifampin involves:
- a) Inhibition of mycolic acid synthesis.
- b) Inhibition of bacterial DNA-dependent RNA polymerase.
- c) Disruption of the bacterial cell membrane.
- d) Inhibition of arabinosyl transferase.
Answer: b) Inhibition of bacterial DNA-dependent RNA polymerase.
18. A patient is diagnosed with active TB and is also HIV-positive, taking an efavirenz-based antiretroviral regimen. What is the concern with co-administering rifampin?
- a) Rifampin will increase efavirenz levels, causing toxicity.
- b) Rifampin will decrease efavirenz levels, potentially leading to HIV treatment failure.
- c) Efavirenz will inactivate rifampin.
- d) There is no interaction between these two medications.
Answer: b) Rifampin will decrease efavirenz levels, potentially leading to HIV treatment failure.
19. What is a common alternative to rifampin in HIV-positive patients on protease inhibitors to avoid significant drug interactions?
- a) Rifabutin
- b) Rifapentine
- c) Isoniazid
- d) Ethambutol
Answer: a) Rifabutin
20. A patient on RIPE therapy calls the pharmacy complaining of numbness and tingling in their hands and feet. This symptom is most likely caused by which medication?
- a) Rifampin
- b) Isoniazid
- c) Pyrazinamide
- d) Ethambutol
Answer: b) Isoniazid
21. Before initiating ethambutol, it is crucial to obtain a baseline:
- a) Electrocardiogram (ECG)
- b) Serum creatinine
- c) Vision exam
- d) Chest X-ray
Answer: c) Vision exam
22. Which of the first-line TB drugs is most associated with causing drug-induced lupus erythematosus?
- a) Rifampin
- b) Isoniazid
- c) Pyrazinamide
- d) Ethambutol
Answer: b) Isoniazid
23. The continuation phase of TB treatment is designed to:
- a) Rapidly decrease the bacterial load.
- b) Prevent the emergence of drug resistance.
- c) Eradicate the remaining, persistent mycobacteria.
- d) Treat latent TB infection.
Answer: c) Eradicate the remaining, persistent mycobacteria.
24. For a patient with a TST induration of 7 mm, which of the following conditions would make this a “positive” test for LTBI?
- a) The patient is a healthcare worker.
- b) The patient is a recent contact of a person with infectious TB.
- c) The patient has no known risk factors.
- d) The patient is a foreign-born person from a low-prevalence country.
Answer: b) The patient is a recent contact of a person with infectious TB.
25. A 4-month course of daily rifampin is an accepted treatment regimen for:
- a) Active TB
- b) Latent TB Infection (LTBI)
- c) MDR-TB
- d) Atypical mycobacterial infections
Answer: b) Latent TB Infection (LTBI)
26. The primary mode of transmission for Mycobacterium tuberculosis is:
- a) Contaminated food or water.
- b) Bloodborne contact.
- c) Inhalation of airborne respiratory droplets.
- d) Sexual contact.
Answer: c) Inhalation of airborne respiratory droplets.
27. Pyrazinamide is most active against mycobacteria in what type of environment?
- a) A neutral pH environment.
- b) An alkaline environment.
- c) An acidic intracellular environment (e.g., within lysosomes).
- d) An oxygen-rich environment.
Answer: c) An acidic intracellular environment (e.g., within lysosomes).
28. A patient on RIPE therapy presents with elevated LFTs (3-5 times the upper limit of normal) but is asymptomatic. What is the most appropriate next step?
- a) Discontinue all four drugs immediately.
- b) Continue all drugs and recheck LFTs in one week.
- c) Add a hepatoprotective agent like milk thistle.
- d) Increase the dose of isoniazid.
Answer: b) Continue all drugs and recheck LFTs in one week.
29. Extensively drug-resistant TB (XDR-TB) is defined as MDR-TB with additional resistance to:
- a) Any two second-line drugs.
- b) Any fluoroquinolone and at least one of the three second-line injectable drugs.
- c) Ethambutol and Pyrazinamide.
- d) All oral TB medications.
Answer: b) Any fluoroquinolone and at least one of the three second-line injectable drugs.
30. Which of the following is considered a second-line agent for the treatment of drug-resistant TB?
- a) Amoxicillin
- b) Bedaquiline
- c) Doxycycline
- d) Metronidazole
Answer: b) Bedaquiline
31. The “gold standard” for diagnosing active pulmonary TB is:
- a) Tuberculin skin test (TST)
- b) Chest X-ray showing cavitary lesions.
- c) Sputum culture positive for M. tuberculosis.
- d) Interferon-Gamma Release Assay (IGRA).
Answer: c) Sputum culture positive for M.tuberculosis.
32. What is the primary reason for using combination therapy to treat active TB?
- a) To shorten the duration of treatment to one month.
- b) To reduce the cost of medication.
- c) To prevent the development of drug-resistant strains of M. tuberculosis.
- d) To minimize all side effects.
Answer: c) To prevent the development of drug-resistant strains of M. tuberculosis.
33. What is the mechanism of action of ethambutol?
- a) It inhibits protein synthesis.
- b) It inhibits mycolic acid synthesis.
- c) It inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis.
- d) It inhibits DNA gyrase.
Answer: c) It inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis.
34. A patient should be counseled to take isoniazid on an empty stomach because:
- a) It causes severe nausea with food.
- b) Food, particularly high-fat meals, can decrease its absorption.
- c) It interacts with dairy products.
- d) It must be taken with a full glass of water.
Answer: b) Food, particularly high-fat meals, can decrease its absorption.
35. A patient on pyrazinamide should be advised to avoid which of the following?
- a) Dairy products
- b) Excessive alcohol consumption due to increased risk of hepatotoxicity.
- c) Grapefruit juice
- d) Leafy green vegetables
Answer: b) Excessive alcohol consumption due to increased risk of hepatotoxicity.
36. Treatment of TB in pregnant women should generally:
- a) Be delayed until after delivery.
- b) Consist of a standard regimen, but with the exclusion of pyrazinamide in some cases due to lack of teratogenicity data.
- c) Involve only two drugs to minimize fetal exposure.
- d) Be managed with second-line agents exclusively.
Answer: b) Consist of a standard regimen, but with the exclusion of pyrazinamide in some cases due to lack of teratogenicity data.
37. Extrapulmonary TB refers to:
- a) A TB infection that is resistant to all drugs.
- b) A TB infection that occurs outside of the lungs.
- c) Latent TB infection.
- d) A TB infection that has resolved.
Answer: b) A TB infection that occurs outside of the lungs.
38. Which of the following is a key role for a pharmacist in TB care?
- a) Performing sputum induction.
- b) Reading chest X-rays.
- c) Counseling patients on medication adherence and managing side effects.
- d) Administering the TST.
Answer: c) Counseling patients on medication adherence and managing side effects.
39. A patient on RIPE therapy develops jaundice (yellowing of the skin and eyes) and dark urine. This is a sign of what serious adverse effect?
- a) Optic neuritis
- b) Peripheral neuropathy
- c) Severe hepatotoxicity
- d) Renal failure
Answer: c) Severe hepatotoxicity
40. A sputum sample is tested using an acid-fast bacillus (AFB) smear. What does a positive result indicate?
- a) Definitive diagnosis of active TB.
- b) Presence of mycobacteria, which could be M. tuberculosis or other species.
- c) The patient has latent TB.
- d) The patient is not contagious.
Answer: b) Presence of mycobacteria, which could be M. tuberculosis or other species.
41. The BCG vaccine is a live attenuated strain used in many countries to prevent severe forms of TB in children. A person who has received the BCG vaccine will likely have:
- a) Lifelong immunity to TB.
- b) A negative TST result.
- c) A positive TST result, which may complicate interpretation.
- d) A negative IGRA result.
Answer: c) A positive TST result, which may complicate interpretation.
42. Which second-line drug class for MDR-TB is associated with a risk of QT prolongation?
- a) Aminoglycosides
- b) Fluoroquinolones
- c) Ethionamide
- d) Cycloserine
Answer: b) Fluoroquinolones
43. A patient with latent TB infection:
- a) Is actively sick and can spread TB to others.
- b) Has a normal chest X-ray and a negative sputum smear.
- c) Does not have M. tuberculosis in their body.
- d) Has a positive TST or IGRA but is not infectious and has no symptoms.
Answer: d) Has a positive TST or IGRA but is not infectious and has no symptoms.
44. What is the purpose of the continuation phase of TB therapy?
- a) To kill rapidly dividing bacilli.
- b) To sterilize the sputum.
- c) To eliminate the remaining persistent bacilli and prevent relapse.
- d) To diagnose drug resistance.
Answer: c) To eliminate the remaining persistent bacilli and prevent relapse.
45. Which of the following is NOT a first-line drug for treating tuberculosis?
- a) Isoniazid
- b) Rifampin
- c) Moxifloxacin
- d) Pyrazinamide
Answer: c) Moxifloxacin
46. If a patient on RIPE therapy experiences significant nausea, a pharmacist might recommend:
- a) Discontinuing all medications immediately.
- b) Taking the medications with a small snack or at bedtime.
- c) Doubling the dose of the medications.
- d) Adding an antacid to their regimen.
Answer: b) Taking the medications with a small snack or at bedtime.
47. A patient with a history of a gout flare should be monitored carefully if started on which TB medication?
- a) Isoniazid
- b) Rifampin
- c) Ethambutol
- d) Pyrazinamide
Answer: d) Pyrazinamide
48. How long must a patient with active, drug-susceptible pulmonary TB be isolated to prevent transmission?
- a) For the entire 6-month treatment course.
- b) Until they have completed the initial 2-month phase of treatment.
- c) Until they have had three consecutive negative sputum smears and are on effective therapy.
- d) Isolation is not necessary for TB.
Answer: c) Until they have had three consecutive negative sputum smears and are on effective therapy.
49. An asymptomatic patient with a positive TST and a normal chest X-ray is diagnosed with LTBI. The main reason to treat this condition is to:
- a) Prevent the patient from spreading TB to others.
- b) Prevent the latent infection from progressing to active TB disease in the future.
- c) Improve the patient’s current symptoms.
- d) Cure the infection within one month.
Answer: b) Prevent the latent infection from progressing to active TB disease in the future.
50. What is a critical factor in the success of any tuberculosis treatment regimen?
- a) The brand name of the medications used.
- b) The patient’s adherence to the full course of therapy.
- c) The time of day the medications are taken.
- d) The patient’s insurance coverage.
Answer: b) The patient’s adherence to the full course of therapy.
